U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
Cancer Therapy Advisor

Pathologic Complete Response vs ctDNA Remains Essential for Solid Cancer Prognostication

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...
Medscape

Neoadjuvant Therapy Use Rising Sharply in Cancer Care

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...
ascopubs.org

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized ...

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer Neoadjuvant approaches ...
Medical Xpress

ctDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...
ascopubs.org

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter ...

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial This study of a novel HER2-targeting ADC ...
Nasdaq

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
The American Journal of Managed Care

Integrating Durvalumab and Atezolizumab Into Neoadjuvant and Adjuvant Sequencing Strategies for Resectable NSCLC

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data. This episode, titled Integrating Durvalumab and ...